Patients May Not Feel Benefits of Medicare Drug Price Negotiations

By on October 4, 2023

The Biden administration recently announced a list of Medicare-covered drugs that will be subject to price negotiations. The administration said the negotiations—a reality thanks to the Inflation Reduction Act—will benefit nearly nine million seniors.

However, according to this Insider article, some drug-policy analysts seem unconvinced by the administration’s claims.

Access the article.

Jeffrey Davis
Jeffrey is a skilled healthcare executive with substantial knowledge of regulatory advocacy and healthcare policies. Jeffrey’s work focuses on issues tied to provider payment and reimbursement as well as quality reporting. He also has significant experience with recent regulatory developments such as the implementation of surprise billing rules. Read Jeffrey Davis's full bio.




Top ranked chambers 2022
US leading firm 2022